LTS and GRAMME Partner for Biologic Delivery

A strategic agreement has been established between LTS LOHMANN Therapie-Systeme AG (LTS) and Grand River Aseptic Manufacturing (GRAMME) to provide pharmaceutical firms a turnkey solution for the development and production of wearable injectors intended exclusively for the delivery of biologics. The partnership seeks to expedite access to markets and streamline manufacturing procedures. For viscous and/or high-volume drug formulations, Sorrel is a next-generation on-body delivery technology that is intended to maximise pharmaceutical efficiency and patient convenience. For at-home delivery, its unique technology enables a variety of medications and indications.

 Scalable manufacturing services, regulatory assistance, sterile production, and support for product development are all provided by GRAMME, an aseptic fill and finish CDMO. By combining LTS's patented SorrelTM drug delivery technology with GRAM's fill-finish experience, the partnership seeks to help clients' path from molecule to market. By facilitating the adoption of advanced therapies, the alliance hopes to improve patient care and develop technology.